483
Robin CornelissenRobin Cornelissen – FDA 483, Apr 8, 2022
Record Details
During an inspection from April 4-8, 2022, the FDA observed that Robin Cornelissen, MD, a Principal Investigator in Rotterdam, Netherlands, failed to maintain accurate case histories. Specifically, the firm did not report numerous adverse events documented in subjects' source records for a clinical protocol. This indicates a significant lapse in clinical trial record-keeping and adverse event reporting.
View Company Profile
ID · df50166f-3712-44af-aa10-d70c3d0eca30
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.